Mogrify awarded $1.1M additional funding from SBRI Healthcare

• Phase II funding will be used for pre-clinical assessment of regenerative cartilage therapy • Follows Phase I SBRI funding, announced in April 2019

CEO Update | Monday 27 January 2020

The launch of our annual finance report: ‘Global and growing: UK biotech financing in 2019’ was well received by members and the media.  The report shows that the UK biotech sector is heading into the new decade in a very strong position. 2019 was the third best year recorded by the BIA and the fifth consecutive year in which more than £1bn was raised. We have seen a drop in investment globally, across all countries and sectors but it’s clear that UK biotech companies remain an attractive investment opportunity for global investors.

Coulter Partners secures Chief Scientific Officer for OxStem

Coulter Partners was very pleased to partner once again with OxStem Limited to secure the appointment of Dr. Ian Churcher to the role of Chief Scientific Officer.

Coulter Partners secures Head of US Sales for Nanoform

Coulter Partners was delighted to partner once again with innovative nanoparticle medicine enabling company, Nanoform to secure the appointment of Sally Langa as Head of US Sales. The new role will enable Nanoform to continue its rapid growth with a strengthened presence in the US market.

NEW REPORT SHOWS IMPACT OF DISCOVERY PARK COMMUNITY LAB ON STEM EDUCATION

FUTURE PLANS TO INSPIRE MORE STUDENTS & INCREASE RANGE OF ACTIVITIES

UK biotech records third highest year for investment despite global uncertainty

New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019. The total is the third highest year recorded by the trade association and since 2012 investment has increased by over 400%

Horizon Discovery grants a multi-product use license of its GS knockout CHO K1 cell line to NGM Bio

Cell line to be used to support research and development of biotherapeutics across therapeutic areas

PhoreMost enters multi-project drug discovery collaboration with Otsuka Pharmaceutical

• PhoreMost’s next-generation phenotypic screening platform, SITESEEKER, to identify novel targets for Otsuka’s therapeutics discovery programmes • Programmes to initially focus on gene therapy applications of identified targets

CEO Update|Monday 20 January

After a week of big UK announcements at JP Morgan in San Francisco, I am delighted that the positive momentum for our sector will be sustained with the release of our annual biotech financing report later this week. I look forward to celebrating the report’s findings and our sector’s successes at the premier bioscience networking event of the year, the BIA annual Gala Dinner.

Arecor to participate At PEPTalk 2020’s Protein Science Week In San Diego, CA, USA

Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces Dr Jan Jezek, Chief Scientific Officer, will present at PEPTalk 2020, in San Diego, California, USA on 20-24 January 2020.